테르부탈린

동물 종별 용량

투여 경로

금기

• Known hypersensitivity to terbutaline
• Heart disease (especially congestive heart failure or cardiomyopathy)
• Known hypersensitivity to terbutaline or sympathomimetic amines
• Severe cardiac arrhythmias
• Hypertrophic cardiomyopathy (relative contraindication)

이상반응

• Increased heart rate (tachycardia)
• Tremors
• CNS excitement (nervousness)
• Dizziness
• Sweating (reported in horses after parenteral injection)
• Transient hypokalemia
• Tachycardia
• Muscle tremors
• Restlessness or excitement
• Hypokalemia (with high doses or prolonged use)
• Hypertension or hypotension

약물 상호작용

• Inhalation Anesthetics (e.g., halothane, isoflurane, methoxyflurane) · May predispose the patient to ventricular arrhythmias, particularly with preexisting cardiac disease; use cautiously.
• Beta-Adrenergic Blocking Agents (e.g., propranolol) · May antagonize the bronchodilating and cardiovascular actions of terbutaline.
• Digoxin · Concurrent use with digitalis glycosides may increase the risk of cardiac arrhythmias. · moderate
• Monoamine Oxidase Inhibitors (MAOIs) · May potentiate the vascular effects of terbutaline.
• Other Sympathomimetics · May increase the risk of developing adverse cardiovascular effects.
• Tricyclic Antidepressants · May potentiate the vascular effects of terbutaline.
• Beta-blockers (e.g., propranolol) · Antagonize the bronchodilating effects of terbutaline · major
• Sympathomimetics · Additive cardiovascular toxicity and CNS stimulation · moderate
• Inhalant anesthetics (e.g., halothane) · Sensitize the myocardium, increasing the risk of severe arrhythmias · major
• Tricyclic antidepressants (TCAs) / MAOIs · May potentiate vascular effects · moderate

모니터링

• Clinical symptom improvement (respiratory rate/effort)
• Auscultation of lung sounds
• Cardiac rate and rhythm (especially if indicated for arrhythmias or if tachycardia develops)
• Serum potassium (early in therapy if the animal is susceptible to hypokalemia)
• Heart rate and rhythm
• Respiratory rate and effort
• Serum potassium levels (with prolonged or high-dose therapy)

과용량

Clinical signs of significant systemic overdose may include **arrhythmias** (bradycardia, tachycardia, heart block, extrasystoles), **hypertension, fever, vomiting, mydriasis, and CNS stimulation**. **Treatment:** - For recent oral ingestion without significant cardiac/CNS effects: Empty gut, administer activated charcoal, and a cathartic. - For severe cardiac arrhythmias: A beta-blocking agent (e.g., propranolol) can be used, but **caution is advised** as it may precipitate severe bronchoconstriction.